Article in BioCentury: Adrecizumab shows apparent mortality benefit in septic shock trial

29. April 2021

April 2021,
by Stephen Hansen

Download

Search for:

Adrenomed Receives Positive EMA Scientific Advice for Further Clinical Development of Adrecizumab in Septic Shock

2. December 2021

Adrenomed Announces Participation in Scientific and Industry Events in September and October 2021

30. August 2021

#DeutschlandErkenntSepsis

22. February 2021

Adrenomed Supervisory Board appoints Dr. Wolfgang Baiker as CEO

4. January 2021

Efficacy Data from Adrenomed’s AdrenOSS-2 Phase II trial evaluating Adrecizumab (HAM8101) in Septic Shock presented at DIVI

2. December 2020

Adrenomed closes EUR 22 million equity financing to accelerate development of Adrecizumab (HAM8101) and provides business update

30. November 2020

More News

Media Coverage

Article in Handelsblatt: Kampf gegen Sepsis – Adrenomed könnte nächste deutsche Biotech-Erfolgsgeschichte werden

19. October 2021

Article in Nature Biopharma Dealmakers: The key to treating sepsis and septic shock: matching treatment to causal pathophysiology

28. July 2021

Interview with Deutsche Welle: Is it becoming easier to get financing for innovation?

19. May 2021

Article in BioCentury: Adrecizumab shows apparent mortality benefit in septic shock trial

29. April 2021

Article in BioWorld: Adrecizumab shows apparent mortality benefit in septic shock trial

16. September 2020

Article in BioWorld: Adrenomed’s adrecizumab shows hints of efficacy in open-label COVID-19 study

28. August 2020

Recent Events

Participation in Virtual J.P. Morgan 40th Annual Healthcare Conference 2022, 10 – 13 January 2022

26. November 2021

Weimar Sepsis Update, September 8 – 10, 2021

23. August 2021

ISICEM, August 31 – September 3, 2021

23. August 2021

BIO Digital, 10–18 June, 2021

7. June 2021

Bio€quity Europe, 17–19 May, 2021

19. April 2021

BIO-Europe Spring, 22-25 March, 2021

15. March 2021

More Events

Article in BioCentury: Adrecizumab shows apparent mortality benefit in septic shock trial

Recent News

Adrenomed Receives Positive EMA Scientific Advice for Further Clinical Development of Adrecizumab in Septic Shock

Adrenomed Announces Participation in Scientific and Industry Events in September and October 2021

#DeutschlandErkenntSepsis

Adrenomed Supervisory Board appoints Dr. Wolfgang Baiker as CEO

Efficacy Data from Adrenomed’s AdrenOSS-2 Phase II trial evaluating Adrecizumab (HAM8101) in Septic Shock presented at DIVI

Adrenomed closes EUR 22 million equity financing to accelerate development of Adrecizumab (HAM8101) and provides business update

Media Coverage

Article in Handelsblatt: Kampf gegen Sepsis – Adrenomed könnte nächste deutsche Biotech-Erfolgsgeschichte werden

Article in Nature Biopharma Dealmakers: The key to treating sepsis and septic shock: matching treatment to causal pathophysiology

Interview with Deutsche Welle: Is it becoming easier to get financing for innovation?

Article in BioCentury: Adrecizumab shows apparent mortality benefit in septic shock trial

Article in BioWorld: Adrecizumab shows apparent mortality benefit in septic shock trial

Article in BioWorld: Adrenomed’s adrecizumab shows hints of efficacy in open-label COVID-19 study

Recent Events

Participation in Virtual J.P. Morgan 40th Annual Healthcare Conference 2022, 10 – 13 January 2022

Weimar Sepsis Update, September 8 – 10, 2021

ISICEM, August 31 – September 3, 2021

BIO Digital, 10–18 June, 2021

Bio€quity Europe, 17–19 May, 2021

BIO-Europe Spring, 22-25 March, 2021

Archive